Biopharmaceutical Contract Development and Manufacturing (CDMO) Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

8. 3.8. Product Pipeline Analysis

9. 3.9. Incidence and Prevalence Analysis

10. 3.10. Patent Analysis

4. TECHNOLOGICAL OUTLOOK

5. BIOPHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET BY SERVICE TYPE

1. 5.1. Introduction

2. 5.2. Drug Development Services

3. 5.3. Process Development & Optimization

4. 5.4. Analytical & Quality Testing Services

5. 5.5. Clinical Manufacturing

6. 5.6. Commercial Manufacturing

7. 5.7. Fill-Finish Services

8. 5.8. Packaging & Labeling Services

6. BIOPHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET BY MOLECULE TYPE

1. 6.1. Introduction

2. 6.2. Biologics

3. 6.3. Biosimilars

4. 6.4. Advanced Therapy Medicinal Products (ATMPs)

7. BIOPHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET BY END-USER

1. 7.1. Introduction

2. 7.2. Pharmaceutical Companies

3. 7.3. Biotechnology Firms

4. 7.4. Emerging Biotech Startups

5. 7.5. Research Institutes

6. 7.6. Government Organizations

8. BIOPHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. Lonza Group AG

2. 10.2. Catalent, Inc.

3. 10.3. WuXi Biologics

4. 10.4. Boehringer Ingelheim

5. 10.5. Thermo Fisher Scientific

6. 10.6. AGC Biologics

7. 10.7. Rentschler Biopharma SE

8. 10.8. Fujifilm Diosynth Biotechnologies

9. 10.9. Charles River Laboratories

10. 10.10. Siegfried Holding AG

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations